•
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion last week regarding the approval of Eli Lilly and Company’s (NYSE: LLY) Kisunla (donanemab) for the treatment of early Alzheimer’s disease (AD). Despite this setback, the US pharmaceutical giant stated that…
•
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to the US Food and Drug Administration (FDA) for LAE102, an Activin Receptor Type 2 A (ActRIIA)-targeted monoclonal antibody (mAb) co-developed with Eli Lilly & Co. (NYSE: LLY). Collaboration DetailsUnder the agreement signed between Laekna and…
•
US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly Gateway Laboratory (LGL) in China. This state-of-the-art facility, the fourth of its kind globally, is equipped with first-class ready-to-use laboratories, shared meeting rooms, and convenient workstations. The laboratory is designed to support the growth of…
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient delivery option designed to provide cash-paying patients with all dose strengths of Wegovy at a reduced cost of USD 499 per month. Program DetailsThe introduction of NovoCare Pharmacy mirrors the approach taken by US major…
•
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with Eli Lilly & Co. (NYSE: LLY). The alliance aims to discover, develop, and commercialize molecular glue therapeutics in oncology. Collaboration DetailsSpecifically, Magnet’s TrueGlue discovery platform will be utilized to identify molecular glues capable of inducing…
•
US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical manufacturing sites in the United States. The move aims to boost the company’s domestic medicine production across various therapeutic areas. API Manufacturing and Supply Chain StrengtheningThree of the new sites will focus on manufacturing active…
•
Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide) for self-pay patients with obesity, priced at USD 499 under the new Zepbound Self Pay Journey Program. Dosing OptionsThe program offers self-pay patients a range of Zepbound doses: 2.5 mg,…
•
US-based Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical-stage biotech focused on inflammatory bowel disease (IBD), announced that its FXR program, including lead asset FXR314, has been acquired by Eli Lilly and Company (NYSE: LLY). The transaction grants Lilly global commercial and intellectual property rights to the program. Transaction DetailsUnder the…
•
Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage radiopharmaceutical company, to develop targeted alpha therapies for various cancers. The partnership will leverage AdvanCell’s Pb-212 production technology and Lilly’s drug development expertise. Collaboration DetailsThe agreement combines AdvanCell’s proprietary radionuclide infrastructure with Lilly’s drug candidate…
•
Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a South Korea-based RNAi therapeutics developer, to jointly develop and commercialize OLX75016, an investigational drug targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications. Drug ProfileOLX75016, derived from a genome-wide association study (GWAS), is…
•
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues climbing 45% year-on-year (YOY) to reach USD 13.53 billion. The surge was primarily fueled by its GLP-1 drugs Mounjaro and Zepbound (tirzepatide). Excluding these incretin-focused drugs, Lilly’s overall portfolio still expanded by 20% YOY. For…
•
US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have announced the launch of the Young Institute Pharmaceutical Manufacturing Consortium in collaboration with Purdue University. The initiative aims to develop new methods of drug manufacturing, driving technological innovation in the pharmaceutical industry. Consortium Focus and…
•
France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US FDA has lifted a clinical hold on its planned Actual Use Trial (AUT) for Cialis (tadalafil). This move allows Sanofi to initiate the AUT and potentially switch the PDE5 inhibitor from a prescription to an…
•
US major Eli Lilly and Company (NYSE: LLY) has announced receiving marketing approval from the US FDA for its Omvoh (mirikizumab-mrkz), an interleukin-23p19 (IL-23p19) antagonist, to treat moderately to severely active Crohn’s disease in adults. This approval follows the FDA’s nod for its use as a first-in-class treatment for moderately…
•
Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture Fund, a venture capital fund backed by Eli Lilly and Company (NYSE: LLY). The fund is designed to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring…
•
US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3Kα inhibitor currently being studied in a Phase I/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move…
•
US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly and Company (NYSE: LLY) to advance its investigational drug MTX-463 into a Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). This strategic partnership aims to further develop and potentially bring to…
•
US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm Scorpion Therapeutics, with the aim of acquiring the oncology biotech for a potential USD 2.5 billion. This strategic move is expected to significantly expand Eli Lilly’s presence in the oncology sector. Deal Details and TimelineAccording…
•
UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition. Agreement DetailsUnder…
•
Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has announced his departure to seek external development opportunities, according to local media. His last day in the role will be January 14, 2025. Career Highlights at Eli Lilly ChinaDuring his tenure at Eli Lilly China,…